{
    "clinical_study": {
        "@rank": "154902", 
        "arm_group": [
            {
                "arm_group_label": "Finacea 15% Gel (azelaic acid 15%), Brimonidine 15 % Gel", 
                "arm_group_type": "Experimental", 
                "description": "Finacea 15% Gel  (azelaic acid 15%) followed 30 minutes later with application of Brimonidine 0.33% Gel each morning to the face\nFinacea 15 % Gel  (azelaic acid 15%) each evening to the face"
            }, 
            {
                "arm_group_label": "Brimonidine 0.33% Gel", 
                "arm_group_type": "Active Comparator", 
                "description": "Brimonidine 0.33% Gel applied to the face each morning"
            }
        ], 
        "brief_summary": {
            "textblock": "The pilot study will investigate whether combination treatment of Finacea 15% Gel and\n      Brimonidine 0.33% Gel could be more effective than Brimonidine 0.33%  Gel monotherapy in\n      treating both the papules/pustules and erythema associated with rosacea."
        }, 
        "brief_title": "Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acne Rosacea", 
        "condition_browse": {
            "mesh_term": "Rosacea"
        }, 
        "detailed_description": {
            "textblock": "Acne rosacea is a chronic inflammatory disease with different components including\n      inflammatory lesions (papules/pustules), erythema and telangiectasia. Brimonidine 0.33% Gel\n      primarily affects the erythematous components of rosacea. As such, combination treatment\n      with a standard rosacea treatment, such as Finacea 15% Gel, may provide additional relief\n      for the inflammatory component of rosacea."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or Female\n\n          -  18 years of age and older\n\n          -  Female subjects of childbearing potential must have a negative urine     pregnancy\n             test at Baseline\n\n          -  Female subjects of childbearing potential must practice a reliable method of\n             contraception throughout the study\n\n          -  Moderate or severe rosacea with an Investigator Global Assessment  (IGA) score of 3\n             or 4\n\n          -  Able to understand and comply with the requirements of the study and sign Informed\n             Consent/Health Insurance Portability and Accountability Authorization forms\n\n        Exclusion Criteria:\n\n          -  Female subjects who are pregnant, breast feeding or who are  of childbearing\n             potential and not practicing a reliable method of birthcontrol\n\n          -  History of hypersensitivity or idiosyncratic reaction to any component of the test\n             medications\n\n          -  Subjects who have not completed the proper wash-out periods for prohibited\n             medications and/or procedures\n\n          -  Medical condition that contraindicates the subject's participation in the study\n\n          -  Alcohol or drug abuse is evident within the past 5 years\n\n          -  History of poor cooperation, non-compliance with medical treatment, unreliability\n\n          -  Participation in an investigational drug study within 30 days of the Baseline visit"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02147691", 
            "org_study_id": "FIN1302"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Finacea 15% Gel (azelaic acid 15%), Brimonidine 15 % Gel", 
                    "Brimonidine 0.33% Gel"
                ], 
                "intervention_name": "Azelaic acid 15%", 
                "intervention_type": "Drug", 
                "other_name": "Finacea"
            }, 
            {
                "arm_group_label": "Finacea 15% Gel (azelaic acid 15%), Brimonidine 15 % Gel", 
                "intervention_name": "Brimonidine 0.33%", 
                "intervention_type": "Drug", 
                "other_name": "Miravaso"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Azelaic acid", 
                "Brimonidine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 22, 2014", 
        "location": {
            "contact": {
                "email": "wedoderm@yahoo.com", 
                "last_name": "Leon H. Kircik, M.D.", 
                "phone": "502-451-9000"
            }, 
            "contact_backup": {
                "email": "wedoderm@yahoo.com", 
                "last_name": "Deborah B. Zuidema, M.S.N.", 
                "phone": "502-456-4161"
            }, 
            "facility": {
                "address": {
                    "city": "Louisville", 
                    "country": "United States", 
                    "state": "Kentucky", 
                    "zip": "40217"
                }, 
                "name": "DermResearch, PLLC"
            }, 
            "investigator": {
                "last_name": "Leon H. Kircik, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study", 
        "other_outcome": {
            "description": "Through out the study, subjects will be monitored for signs and symptoms of adverse events. Adverse events will be collected regardless of whether related to study drug application or not.", 
            "measure": "Adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline, Week 4, Week 8, Week 12"
        }, 
        "overall_contact": {
            "email": "wedoderm@yahoo.com", 
            "last_name": "Leon H. Kircik, M.D.", 
            "phone": "502-451-9000"
        }, 
        "overall_contact_backup": {
            "email": "wedoderm@yahoo.com", 
            "last_name": "Deborah B. Zuidema, M.S.N.", 
            "phone": "502-456-4161"
        }, 
        "overall_official": {
            "affiliation": "DermResearch, PLLC", 
            "last_name": "Leon H. Kircik, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessment of rosacea on a scale of 0-4, 0 = clear, 1= almost clear, 2= mild, 3= moderate and 4 = severe", 
            "measure": "Change in Investigator Global Assessment", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 4, Week 8, Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02147691"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Derm Research, PLLC", 
            "investigator_full_name": "Leon Kircik, M.D.", 
            "investigator_title": "Medical Director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The number of inflammatory lesions (papules/pustules) will be counted using  the whole face from the hairline edge to the mandibular line", 
                "measure": "Lesion counts", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 4, Week 8 and Week 12"
            }, 
            {
                "description": "Erythema will be graded  on a scale of 0-4., 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4  very severe. If erythema is much worse on one or several parts of the face, the grade for the worst area will be captured.", 
                "measure": "Clinician's Erythema assessment", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 4, Week 8 and Week 12"
            }, 
            {
                "description": "Subjects will self assess the level of erythema over the previous 24 period using a scale of None (0) through 10 (Unbearable)", 
                "measure": "Erythema VAS Assessment (Subject)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 4, Week 8, Week 12"
            }, 
            {
                "description": "The DLQI is a self-administered questionnaire consisting of 10 questions that measure how much the individual's  skin problem has affected their life in the past week.", 
                "measure": "Dermatology Life Quality Index (DLQI)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 4, Week 8, Week 12"
            }
        ], 
        "source": "Derm Research, PLLC", 
        "sponsors": {
            "collaborator": {
                "agency": "Bayer Healthcare Pharmaceuticals Inc.", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Derm Research, PLLC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}